Last updated March 15, 2022

Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas Aeruginosa Infection

Recommendations

The CF Foundation strongly recommends inhaled antibiotic therapy for the treatment of initial or new growth of P. aeruginosa from an airway culture. (A)
The favored antibiotic regimen is inhaled tobramycin (300 mg twice daily) for 28 days.
322325

The CF Foundation recommends against the use of prophylactic antipseudomonal antibiotics to prevent the acquisition P. aeruginosa. (D)
322325

The CF Foundation recommends routine oropharyngeal cultures rather than bronchoalveolar lavage cultures obtained by bronchoscopy in individuals with CF who cannot expectorate sputum to determine if they are infected with P. aeruginosa. (B)
322325

Recommendation Grading

Overview

Title

Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas Aeruginosa Infection

Authoring Organization

Endorsing Organization

Publication Month/Year

October 5, 2014

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Target Patient Population

Individuals with CF

Inclusion Criteria

Female, Male, Adolescent, Adult, Child, Infant, Older adult

Health Care Settings

Emergency care, Hospital, Outpatient

Intended Users

Respiratory therapist, nurse, nurse practitioner, physician, physician assistant

Scope

Diagnosis, Prevention, Management, Treatment

Diseases/Conditions (MeSH)

D003550 - Cystic Fibrosis

Keywords

cystic fibrosis, Pseudomonas aeruginosa